ArriVent BioPharma, Inc. (AVBP) Stock Price & Analysis

ArriVent BioPharma, Inc. (AVBP) is trading at USD 10.7, up 0.09% today, as of November 18, 2026 at 17:02 UTC (US market open; quotes may be delayed), according to Nexqual market data.

AVBP last closed at USD 10.69; today's session has ranged USD 10.33–11.11 on volume of 174,725 shares. Market capitalization is $553.44M, with a 52-week range of USD 10.33–35.83 (NGM). Source: Nexqual, retrieved November 18, 2026 at 17:03 UTC.

What changed for AVBP since Aug 31, 2025

The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

Also available as compact Markdown for AI agents: nexqual.com/AVBP.md

Key facts (AVBP)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AVBP)

USDFY2023FY2024FY2025TTM
Operating income-$74.6M-$94.3M-$178M-$181M
Net income-$69.3M-$80.5M-$166M-$169M
EPS (diluted)-$32.38-$2.56-$4.32—
Cash + short-term investments$150M$219M$313M—

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (AVBP)

P/B 1.4x · Earnings yield -30.55%

Analysts (AVBP)

Consensus Buy (mean 2.00 on a 1–5 scale), 11 analysts; mean target USD 26.2 (low 22, high 29).

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-11-10Truist SecuritiesTarget raisedBuy$21 → $24
2026-10-27GuggenheimTarget raisedBuy$18 → $30
2026-10-20B. Riley SecuritiesTarget loweredBuy$45 → $29
2026-10-16BTIGReiteratedBuy$29
2026-10-08HC Wainwright & Co.Target loweredBuy$47 → $27
2026-10-07CitigroupTarget loweredBuy$40 → $20
2026-10-07Jones TradingTarget loweredBuy$45 → $22
2026-10-07Truist SecuritiesTarget loweredBuy$45 → $18
2026-10-07GuggenheimTarget loweredBuy$45 → $18
2026-10-07BTIGTarget loweredBuy$42 → $29
2026-08-17HC Wainwright & Co.Target raisedBuy$44 → $47
2026-08-13CitigroupTarget loweredBuy$43 → $40

Total return (dividends reinvested) (AVBP)

1Y (from 2025-11-18)5Y (from 2024-01-22)
Total return-47.1%-46.5%
S&P 500 (SPY)+11.8%+66.4%
Per year-47.1%-19.9%
Volatility (annualized)94.0%65.3%
Max drawdown-69.2% (Jun 2026→Nov 2026)-69.2% (Jun 2026→Nov 2026)

Dividends (AVBP)

AVBP paid no cash dividend in the last five years.

Short interest (AVBP)

5,797,018 shares sold short, 11.98% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 8,451,472 shares (-31.4%). Days to cover: 2.4 (short shares ÷ average daily volume).

AVBP major shareholder filing: Schedule 13D/A, Oct 8, 2026

ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P. filed a Schedule 13D/A with the SEC on Oct 8, 2026, reporting up to 5.80% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:

The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. …

Source: SEC EDGAR, Schedule 13D/A filed Oct 8, 2026. Quoted word for word; Nexqual adds no interpretation.

AVBP earnings history and stock reaction

Results filedQuarterEPSConsensusSurpriseStock reaction
Nov 9, 2026Quarter ended Sep 30, 2026−$0.81−$1.06Beat +23.6%-1.1%
Aug 12, 2026————-4.4%
May 11, 2026Quarter ended Mar 31, 2026−$0.96−$0.89Miss −7.9%-1.8%
Mar 5, 2026————-11.8%
Nov 10, 2025Quarter ended Sep 30, 2025−$0.83−$0.78Miss −6.4%+7.4%
Aug 11, 2025————-5.8%
May 12, 2025————-5.2%
Mar 3, 2025————-7.0%

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

AVBP recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 9, 202610-QQuarterly report · period ended Sep 30, 2026
Nov 9, 20268-KQuarterly results; Director or executive officer change, or pay arrangement
“On November 6, 2026, Stuart Lutzker, M.D., Ph.D. notified the Company of his intention to retire from the position of President, Research and Development of the Company and as a director of the Company, effective as of December 1, 2026 (the "Retirement Date"). Dr. Lutzker's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. In connection with Dr. Lutzker's retirement from the Company, the Company intends to enter into a…”
Nov 5, 2026Schedule 13G/AFMR LLC, Abigail P. Johnson: 5.8% of shares, passive 5%+ holder (amended)
Oct 26, 20268-KRegulation FD disclosure; Other material event
Oct 19, 20268-KRegulation FD disclosure
Oct 13, 2026Schedule 13GVivo Opportunity Fund Holdings, L.P., Vivo Opportunity Co-Invest, L.P.: 5.0% of shares, passive 5%+ holder
Oct 13, 20268-KRegulation FD disclosure; Other material event
Oct 8, 2026Schedule 13D/AORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC: 5.8% of shares, 5%+ holder that may seek to influence the company (amended)
“The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from…”
Oct 6, 20268-KRegulation FD disclosure; Other material event
Aug 12, 202610-QQuarterly report · period ended Jun 30, 2026
Aug 12, 20268-KEntered a material agreement; Quarterly results
“On August 11, 2026, ArriVent BioPharma, Inc. (the "Company") entered into a Collaboration and License Agreement (the "Allist License Agreement") with Shanghai Allist Pharmaceuticals Co., Ltd. ("Allist"), a pharmaceutical company incorporated under the laws of China. Pursuant to the Allist License Agreement, the Company granted Allist an exclusive, sublicensable (through multiple tiers), royalty-bearing license under certain intellectual property owned or controlled by the Company to research, develop, manufacture,…”
Jul 27, 2026Schedule 13G/Apassive 5%+ holder (amended)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

AVBP suppliers, customers and competitors (named in its 10-K)

RelationshipCompanySentence in the filing
SupplierWuXi“Currently, we rely on, and have agreements with, two third-party contract manufacturers, Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) to supply the drug substance for firmonertinib to be used in on-going and planned clinical trials and with WuXi STA, with whom we have executed technology transfer related to the manufacture of drug product, to manufacture …”
SupplierSynTheAll Pharmaceutical“Currently, we rely on, and have agreements with, two third-party contract manufacturers, Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) to supply the drug substance for firmonertinib to be used in on-going and planned clinical trials and with WuXi STA, with whom we have executed technology transfer related to the manufacture of drug product, to manufacture …”
SupplierFortrea Holdings Inc. (FTRE)“Specifically, we rely on, and intend to continue to rely on, medical institutions, clinical investigators, CROs, such as Fortrea, Inc., Icon Clinical Research Limited, and Syneos Health, LLC, and consultants to conduct nonclinical studies and clinical trials, in each case in accordance with our study protocols and applicable regulatory requirements.”
SupplierIcon Clinical Research“Specifically, we rely on, and intend to continue to rely on, medical institutions, clinical investigators, CROs, such as Fortrea, Inc., Icon Clinical Research Limited, and Syneos Health, LLC, and consultants to conduct nonclinical studies and clinical trials, in each case in accordance with our study protocols and applicable regulatory requirements.”
SupplierSyneos Health“Specifically, we rely on, and intend to continue to rely on, medical institutions, clinical investigators, CROs, such as Fortrea, Inc., Icon Clinical Research Limited, and Syneos Health, LLC, and consultants to conduct nonclinical studies and clinical trials, in each case in accordance with our study protocols and applicable regulatory requirements.”
PartnerShanghai Allist Pharmaceuticals“The parties have appointed a joint collaboration committee, comprised of representatives from both us and Allist (the Collaboration Committee), to oversee the parties' development activities related to the Licensed Compound under the Allist License Agreement.”
PartnerAarvik Therapeutics“Also in 2021, we entered into a research collaboration, as amended, with Aarvik Therapeutics, Inc. (Aarvik) to leverage its proprietary multi-target, multivalent, site-specific conjugation antibody platform to discover next-generation antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs.”
PartnerLepu Biopharma“In January 2025, we entered into an Exclusive License Agreement (the Lepu Biopharma Agreement) with Lepu Biopharma Co. Ltd. (Lepu Biopharma) pursuant to which Lepu Biopharma granted us the right to develop and commercialize ARR-217 (MRG007), a CD-H17-targeting ADC for gastrointestinal cancers outside greater China, which includes mainland China, Hong Kong, Macau, and Taiwan.”
PartnerJiangsu Alphamab Biopharmaceuticals“Our Alphamab Antibody Drug Conjugate Collaboration”
CompetitorJohnson & Johnson (JNJ)“Companies that compete with us directly on the level of commercialization or development of product candidates targeting EGFR mutation-positive NSCLC include, but are not limited to, AstraZeneca, Johnson & Johnson, Blossom Hill Therapeutics, Dizal Pharmaceutical, Oric Pharmaceuticals, Black Diamond Therapeutics, Inc., Cullinan Therapeutics, Inc., Taiho Pharmaceutical Co., Ltd., Boehringer Ingelheim and Bayer AG.”

Quoted from the company's 10-K filed Mar 5, 2026.

AVBP company outlook (results filed Nov 9, 2026)

Quoted word-for-word from the SEC 8-K results press release.

AVBP analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Dec 2026)$-0.99$-1.01+$0.02$010
Next quarter (ends Dec 2026)$-0.91$-0.98+$0.07$3.1M10
Current fiscal year (ends Dec 2026)$-3.90$-4.34+$0.44$5.0M9
Next fiscal year (ends Dec 2027)$-3.56$-3.81+$0.25$6.8M10

AVBP options: expected move

ExpirationDaysATM implied volatilityExpected move
Nov 20, 20262237.4%±14.3%
Dec 18, 202630114.3%±26.3%
Jan 15, 202758104.6%±33.0%
Apr 16, 202714995.0%±47.8%

30-day implied volatility 122.1% vs 123.3% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of November 18, 2026 at 17:03 UTC)

PriceUSD 10.7
Change▲ 0.09% (up)
Previous CloseUSD 10.69
OpenUSD 10.42
Day RangeUSD 10.33 – 11.11
52-Week RangeUSD 10.33 – 35.83
Volume174,725 shares
Market Cap$553.44M
ExchangeNGM

Technical Analysis (AVBP)

Nexqual's technical model rates AVBP "SELL" based on 2 bullish and 5 bearish signals across 129 daily candles, as of November 18, 2026 at 17:03 UTC.

Overall SignalSELL
RSI (14)25.15 (oversold)
vs SMA50Below (USD 20.2)
MACD-2.39 (negative)

Analyst Ratings (AVBP)

Wall Street analysts rate AVBP "Buy" based on 11 analysts, with a mean price target of USD 26.2 (range USD 22–29), per Nexqual as of November 18, 2026 at 17:03 UTC.

Consensus RatingBuy
Analyst Count11
Mean TargetUSD 26.2
High TargetUSD 29
Low TargetUSD 22
Buy / Hold / Sell11 / 0 / 0

Earnings (AVBP)

Next Earnings Date2026-11-16
EPS EstimateUSD -0.99
Revenue Estimate$0

Recent Earnings History

QuarterActual vs Estimate
2026-09-30USD -0.81 vs est -1.06 ▲ beat
2026-03-31USD -0.96 vs est -0.89 ▼ miss
2025-09-30USD -0.83 vs est -0.78 ▼ miss

Source: Nexqual, November 18, 2026 at 17:03 UTC.

Financials & Fundamentals (AVBP)

Total Revenue$5.00M
Gross Margin+146.46%
Operating Margin-3620.00%
Profit Margin+0.00%
ROE-48.67%
Debt / Equity0
Current Ratio17.64
Total Cash$393.22M
Total Debt$256,000

Source: Nexqual, November 18, 2026 at 17:03 UTC.

Financial Health Score (AVBP)

Nexqual rates ArriVent BioPharma, Inc.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 17:03 UTC.

GrowthMixed — No data
ProfitabilityCritical — Heavily loss-making — early-stage company
Balance SheetStrong — $393M cash, no debt
Cash FlowWeak — Operating cash flow -$161M (FY ended Dec 2025, 10-K)
EfficiencyCritical — ROE -43%, ROA -40.5% (last 4 quarters, SEC)

Ownership (AVBP)

Insider Ownership+1.47%
Institutional Ownership+103.16%
Shares Outstanding51.72M
Float32.01M
Short % of Float+11.98%

Source: Nexqual, November 18, 2026 at 17:03 UTC.

Leadership (AVBP)

ArriVent BioPharma, Inc. is led by Zhengbin Yao, Co-Founder, Chairman, President & CEO, per Nexqual as of November 18, 2026 at 17:03 UTC.

Co-Founder, Chairman, President & CEOZhengbin Yao
Co-Founder, President of Research & Development and DirectorStuart Lutzker
CFO & TreasurerWinston Kung
Co-Founder & COORobin LaChapelle M.A.
Chief Technology OfficerYang Wang

Major Backers & Investors (AVBP)

Notable institutional backers of ArriVent BioPharma, Inc. include Montanova Capital LLC, Infinitum Asset Management, LLC , HHLR Advisors, LTD, according to Nexqual as of November 18, 2026 at 17:03 UTC.

Active Investors

InvestorStake
Montanova Capital LLC9.52%
Infinitum Asset Management, LLC 8.75%
HHLR Advisors, LTD7.6%
Orbimed Advisors LLC.5.85%
FMR, LLC5.74%
Fidelity4.57%
Octagon Capital Advisors LP4.14%
Vivo Capital, LLC3.46%

Index Funds (Passive)

FundStake
BlackRock6.59%
Vanguard Group3.89%

Source: Nexqual, November 18, 2026 at 17:03 UTC.

From ArriVent BioPharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

Partnerships

Legal & Regulatory Risks (Item 1A, quoted)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
CGONCG Oncology, Inc.USD 81.5▲ 3.24%
KODKodiak Sciences IncUSD 96.25▼ 0.57%
BLTEBelite Bio, IncUSD 158.13▲ 0.26%
ORKAOruka Therapeutics, Inc.USD 96.66▲ 0.35%
IBRXImmunityBio, Inc.USD 6.6▲ 5.35%
IMVTImmunovant, Inc.USD 33.55▲ 1.01%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 17:03 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt